Curated News
By: NewsRamp Editorial Staff
November 17, 2026
Cardio Diagnostics Sets Investor Call on Precision CV Tests
TLDR
- Cardio Diagnostics' Dec 10 investor call will detail its NOCAD blood test and FDA breakthrough bid, offering investors an early edge.
- Cardio Diagnostics uses AI with epigenetics and genetics to detect NOCAD from standard blood samples, as explained in its Dec 10 investor call.
- Cardio Diagnostics' blood tests aim to catch hidden heart disease early, making precise cardiovascular prevention more accessible and improving lives.
- Cardio Diagnostics will start testing in India via Dr. Lal PathLabs and Aimil, expanding its AI heart tests to a new international market.
Impact - Why it Matters
This news matters because cardiovascular disease remains the leading cause of death worldwide, and conventional diagnostics often fail to detect NOCAD, leaving patients at risk. Cardio Diagnostics’ blood-based, AI-driven tests could enable earlier, more accurate detection and personalized prevention. The planned FDA Breakthrough Device request and international expansion into India signal progress toward broader access. For investors, the call offers visibility into reimbursement and growth strategies, while clinicians and patients may gain a scalable tool for identifying hidden cardiovascular risk.
Summary
Cardio Diagnostics Holdings (NASDAQ: CDIO) will host an investor conference call on Dec. 10, 2026, at 11 a.m. CT to discuss its precision cardiovascular disease detection and prevention technologies. The call will feature updates on the company’s commercially available Epi+Gen CHD™ and PrecisionCHD™ tests, ongoing and planned studies, reimbursement progress, and strategic growth initiatives.
A key focus will be non-obstructive coronary artery disease (NOCAD), a condition often missed by conventional diagnostics. Cardio Diagnostics plans to present data supporting its blood-based technology for detecting NOCAD and will discuss its anticipated request for FDA Breakthrough Device designation. The call will also cover the commencement of testing in India, the company’s first international market, through partnerships with Dr. Lal PathLabs and Aimil. Cardio Diagnostics’ approach combines epigenetics, genetics, and artificial intelligence to provide scalable cardiovascular risk assessment and early disease detection via standard blood samples. For full details, visit the full press release.
Cardio Diagnostics is an AI-powered precision cardiovascular medicine company focused on making prevention, detection, and management more accessible, personalized, and precise. Its proprietary AI-driven Integrated Genetic-Epigenetic Engine powers clinical tests aimed at improving cardiovascular outcomes. The latest updates on CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. The announcement was distributed by BioMedWire, a specialized communications platform for the biotech, biomed, and life sciences sectors, part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Cardio Diagnostics Sets Investor Call on Precision CV Tests
